[{"id":"037452f4-ed9d-4921-b399-661395ba3e8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04913285","created_at":"2021-06-04T14:53:23.677Z","updated_at":"2024-07-02T16:35:00.535Z","phase":"Phase 1","brief_title":"A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors","source_id_and_acronym":"NCT04913285","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" BRAF mutation • NRAS mutation","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • exarafenib (KIN-2787)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 12/07/2024","primary_completion_date":" 12/07/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-29"}]